FDA update on CBD offers no timetable for action

FDA says it will soon reopen the docket for comments on how it should regulate hemp-derived cannabidiol (CBD) and is considering a “risk-based enforcement policy” to address concerns about the proliferation of CBD products, but the agency still lacks a timetable for when it might lay out a regulatory pathway for foods or supplements that contain the non-psychoactive cannabis ingredient.

https://iegpolicy.agribusinessintelligence.informa.com/PL223276/FDA-update-on-CBD-offers-no-timetable-for-action

Leave a Reply

woocommerce social proof plugin
%d bloggers like this: